


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula I



I

wherein  $R_1$  independently represents one or more, same or different substituents selected from the group consisting of halogen, hydroxy, mercapto, trifluoromethyl, amino,  $(C_1-C_3)$ alkyl,  $(C_2-C_3)$ olefinic group,  $(C_1-C_3)$ alkoxy,  $(C_1-C_3)$ alkylthio,  $(C_1-C_6)$ alkylamino,  $(C_1-C_3)$ alkoxycarbonyl, cyano, carbamoyl, phenyl and nitro, provided that when  $R_1$  represents one substituent, it is in the ortho position, and when  $R_1$  represents more than one substituent, at least one  $R_1$  substituent is in the ortho position;  $R_2$  is one substituent in the ortho position, said substituent being selected from the group consisting of ~~hydrogen~~, halogen, hydroxy, mercapto, trifluoromethyl, amino,  $(C_1-C_3)$ alkyl,  $(C_2-C_3)$ olefinic group,  $(C_1-C_3)$ alkoxy,  $(C_1-C_3)$ alkylthio,  $(C_1-C_6)$ alkylamino,  $(C_1-C_3)$ alkoxycarbonyl, cyano, carbamoyl, phenyl and nitro;

R<sub>3</sub> represents hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>2</sub>-C<sub>3</sub>)olefinic group, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkylthio, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>1</sub>-C<sub>3</sub>)alkoxycarbonyl, phenyl, cyano, carboxy, or carbamoyl;

R<sub>4</sub> represents hydrogen, (C<sub>1</sub>-C<sub>3</sub>)alkyl, or allyl;

Q represents a bond, -SO<sub>2</sub>-, or -C(R<sub>6</sub>)(R<sub>7</sub>)(-O-C=O)-, in which formula R<sub>6</sub> and R<sub>7</sub> independently represent hydrogen, trifluoromethyl, or (C<sub>1</sub>-C<sub>4</sub>)alkyl;

Y represents (C<sub>1</sub>-C<sub>15</sub>)alkyl, (C<sub>2</sub>-C<sub>15</sub>)olefinic group, (C<sub>3</sub>-C<sub>10</sub>)carbocyclic group, or phenyl, any of which is optionally substituted by one or more, same or different substituents represented by the formula R<sub>5</sub>; or Y represents a group of formula -(Z-O)<sub>n</sub>-Z, where Z is a (C<sub>1</sub>-C<sub>3</sub>)alkyl and n is an integer > 1, and no continuous linear sequence of atoms in the group Y exceeds 15;

R<sub>5</sub> represents halogen, hydroxy, mercapto, trifluoromethyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl, amino, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkylthio, (C<sub>1</sub>-

C<sub>6</sub>)alkylamino, (C<sub>1</sub>-C<sub>3</sub>)alkoxycarbonyl, cyano, azido, nitro, -COOH, -CONH<sub>2</sub>, -CONHR', or -CONRR' wherein R and R' stands for (C<sub>1</sub>-C<sub>3</sub>)alkyl;

X represents oxygen or sulphur,

or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

2. (Currently Amended) A compound according to claim 1 wherein independently

- R<sub>1</sub> represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, (C<sub>1</sub>-C<sub>2</sub>)alkyl, (C<sub>2</sub>-C<sub>3</sub>)alkenyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkoxycarbonyl, or cyano.
- R<sub>2</sub> represents one or more, same or different substituents selected from the group consisting of ~~hydrogen~~, fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, (C<sub>1</sub>-C<sub>2</sub>)alkyl,

(C<sub>2</sub>-C<sub>3</sub>)alkenyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy.

- R<sub>3</sub> represents one or more, same or different substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, trifluoromethyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>2</sub>-C<sub>3</sub>)alkenyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkoxycarbonyl, cyano, or carboxy.
- R<sub>4</sub> represents hydrogen, (C<sub>1</sub>-C<sub>2</sub>)alkyl, or allyl.
- X represents oxygen.
- Q represents a bond or -SO<sub>2</sub>-.

Y represents (C<sub>1</sub>-C<sub>6</sub>)alkyl; (C<sub>2</sub>-C<sub>6</sub>)alkenyl; (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; (C<sub>5</sub>-C<sub>8</sub>)cycloalkene group; or phenyl; any of which is optionally substituted by one or more, same or different substituents selected from the group consisting of the formula R<sub>5</sub>, R<sub>5</sub> representing fluoro, chloro, bromo, hydroxy, amino, (C<sub>1</sub>-C<sub>2</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, (C<sub>1</sub>-C<sub>3</sub>)alkoxycarbonyl, cyano, azido, -COOH, -CONH<sub>2</sub>, -CONHR', or -CONR'R' wherein R' represents (C<sub>1</sub>-C<sub>2</sub>)alkyl.

3. (Previously Presented) A compound according to claim 1 or 2 wherein  $R_1$  represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, methyl, or methoxy.

4. (Previously Presented) A compound according to claim 1, wherein  $R_1$  is methyl and  $R_2$  is Cl.

5. (Previously Presented) A compound according to claim 1 selected from the group consisting of

1-Cyclohexyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]urea (Compound 101),

1-Ethyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]urea (Compound 102),

1-[2-[3-Chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-3-phenylurea (Compound 103),

1-Butyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]urea (Compound 104),

1-[2-[3-Chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-3-isopropylurea (Compound 108),

1-[2-[3-Chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-3-propylurea (Compound 109),

1-Methyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]

phenyl]urea (Compound 110),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]  
phenyl]urea (Compound 112),

1-Ethyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-5-fluoro-  
phenyl]urea (Compound 114),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(2,5-dimethylbenzoyl)-  
phenylamino]phenyl]urea (Compound 117),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(4-chloro-2-methylbenzoyl)-  
phenylamino]phenyl]urea (Compound 121),

1-Ethyl-3-[5-bromo-2-[3-fluoro-4-(4-methoxy-2-methylbenzoyl)-  
phenylamino]phenyl]urea (Compound 123),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(2,4,5-trimethylbenzoyl)-  
phenylamino]phenyl]urea (Compound 124),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(4-fluoro-2-methylbenzoyl)-  
phenylamino]phenyl]urea (Compound 125),

1-Ethyl-3-[5-bromo-2-[3-fluoro-4-(2-methylbenzoyl)-  
phenylamino]phenyl]urea (Compound 126),

and salts thereof with pharmaceutically acceptable acids,  
hydrates and solvates.

6. (Previously Presented) A pharmaceutical composition containing as an active ingredient a compound according to claim 1 together with a pharmaceutically acceptable carrier and optionally together with a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamins D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines,  $\beta$ -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

7. (Cancelled)

8. (Currently Amended) A method for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne, ~~characterized in which comprises~~ administering to a patient suffering from at least one of said diseases an effective amount of one or more compounds according to claim 1 as an active ingredient alone, or ~~if necessary~~ optionally together with a pharmaceutically acceptable

carrier, and, optionally, a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines,  $\beta$ -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

9. (Currently Amended) A method of treatment according to claim ~~1~~  
~~comprising administering to a mammal in need of systemic treatment~~  
8, wherein a suitable dose of a compound of formula I of from 0.1 to 200 mg/kg bodyweight, ~~preferably a dose of from 0.2 to 50 mg/kg~~  
~~of mammal bodyweight~~ is administered one or more times daily.

10. (New) A method of treatment according to claim 8 wherein a suitable dose of a compound of formula I of from 0.2 to 50 mg/kg bodyweight is administered one or more times daily.

11. (New) A method for inhibiting interleukin  $1\beta$  or tumour necrosis factor  $\alpha$  secretion, which comprises administering to a mammal or patient in need thereof an effective amount of one or more compounds according to claim 1.



12. (New) A method of treatment according to claim 11, wherein interleukin  $1\beta$  secretion is inhibited.

13. (New) A method of treatment according to claim 11, wherein tumour necrosis factor  $\alpha$  secretion is inhibited.

14. (New) A method of treatment according to claim 11, wherein the compound is administered to the mammal or patient in a dosage range of from 0.1 to 200 mg/kg bodyweight one or more times daily.

15. (New) A method of treatment according to claim 11, wherein the compound is administered to the mammal or patient in a dosage range of from 0.2 to 50 mg/kg bodyweight one or more times daily.